Published in Gene Therapy Weekly, December 1st, 2005
"The induction of tumor protective immunity against neuroblastoma remains a major challenge for active immunotherapy. Fractalkine is a unique Th1 CX3C chemokine known to induce adhesion and migration of leukocytes mediated by both, a membrane-bound and soluble form, respectively."
"Here," wrote Y. Zeng and colleagues, Humboldt University, "we tested the hypothesis that chemokine gene therapy with FKN induces an effective anti-neuroblastoma immune response amplified by targeted...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.